cjc+ipa blend

clinic-standard GH-axis pairing. cjc-1295 + ipamorelin. receptor logic first, blend trial evidence still thin.

tier A · growth hormone · PCAC '24 503A excluded

verdict

the most common peptide-clinic GH-axis stack. CJC-1295 + ipamorelin amplifies pulse amplitude through two separate receptors.

if you're asking how the blend compares to straight HGH — different model. straight HGH delivers exogenous growth hormone at a flat dose, which over time can flatten the pituitary's own pulse pattern. CJC-1295 + ipamorelin hits the GHRH receptor and the ghrelin receptor at the same time and amplifies the body's own pulse. peak GH is lower than HGH. side-effect profile, by mechanism, is gentler. cost is lower. so is the regulatory and legal exposure.

if you're asking what to expect over months — the most consistent subjective win is sleep depth. body-composition shifts over 3-6 months are real but modest, not dramatic. transient flushing, mild water retention, and occasional ghrelin-driven hunger from the ipamorelin half are the typical reported effects. the receptor logic is well-characterized. a formal blend RCT with outcome endpoints has not been done.

if you're asking about the regulatory state — Oct 29, 2024: FDA PCAC voted against ipamorelin for 503A inclusion, citing immunogenicity, peptide impurity concerns, limited route-specific safety data, and serious adverse events in IV gastric-motility research. compounding pharmacies lost the 503A pathway for the ipamorelin half. research-vendor products continue and are not FDA-reviewed. mislabeled peptide products have been documented in market analyses.

based on published evidence and disclosed clinical practice. not medical advice.

why A-tier

A-tier reflects receptor-pair logic and component-level pharmacology. Not S-tier because direct fixed-blend outcome trials and long-term safety data are missing. The blend is plausible, widely used, and still less proven than the clinic market makes it sound.

the core tension

The pharmacology is coherent: GHRH-plus-GHRP stacking amplifies growth hormone output through two receptor pathways. The missing piece is not the receptor story. It is direct fixed-blend outcome trials and long-term safety data.

what it is

two peptides in one vial: CJC-1295, a GHRH analog, and ipamorelin, a selective ghrelin receptor agonist. the pairing is common in peptide-clinic practice, but vial ratios and formulations vary. neither component is FDA-approved. both are on WADA's prohibited list.

what it does

hits both arms of GH release at once. CJC-1295 supplies the GHRH-receptor signal; ipamorelin supplies the ghrelin-receptor signal. Together they amplify pulse amplitude more than either arm alone. The combination is not best described as increasing pulse frequency.

origin

CJC-1295 came from ConjuChem in the early 2000s, intended for adult GH deficiency. ipamorelin was Novo Nordisk in 1998. both stalled short of FDA approval for commercial reasons rather than trial failure. US compounding pharmacies paired them in the 2010s once the receptor-pair logic became obvious. the blend is what applied pharmacology looks like when it gets handed to clinicians.

why researchers are interested

users and clinics report improved sleep depth, training recovery, and modest body-composition shifts over weeks to months. Those outcomes are plausible from GH-axis pharmacology, but still rely more on distributed practice experience than controlled blend trials. Side effects are usually mild in reports: transient flushing, mild water retention, and occasional ghrelin-driven hunger from the ipamorelin half.

does it work

yes on receptor logic, less settled on clinical endpoints. GHRH plus GHRP synergy is established, and ipamorelin's lower-cortisol, lower-prolactin profile was nailed down by Raun in 1998. The missing piece is a formal blend RCT with outcome endpoints. The Oct 29, 2024 FDA PCAC voted against ipamorelin for 503A inclusion, citing immunogenicity, peptide impurity and characterization concerns, limited route-specific safety data, and serious adverse events in IV gastric-motility research. Source quality is part of the evidence problem. Research-vendor products are not FDA-reviewed, and mislabeled products have been documented in market analyses.

claims vs the data

• stacking produces more GH than either alone — supported — established pharmacology. GHRH hits one receptor family on pituitary somatotrophs, GHRP/ghrelin hits another. combined activation produces a 3-5x larger GH pulse. this is textbook, not controversial.
• safer than exogenous HGH — partially true — stimulates endogenous pulsatile release rather than sustained supraphysiologic levels, which is mechanistically gentler. That does not replace controlled long-term safety data for the blend.
• 'clean', no cortisol or prolactin spike — supported — ipamorelin's selectivity is why it's paired with CJC rather than GHRP-2 or GHRP-6. Raun 1998 established this at the pharmacology level and a decade of clinic use confirms it.
• improves sleep, recovery, body composition — partially true — consistent user and clinic reports, and pharmacologically plausible through GH-axis signaling. Direct controlled blend outcome trials are missing.
• FDA-approved for therapeutic use — contradicted — neither component is FDA-approved, and the blend has no approved use. Compounding and research-vendor access do not equal drug approval.
• blend vials maintain labeled ratio indefinitely — unverified — CJC-1295 (3367 Da) and ipamorelin (712 Da) degrade at different rates in reconstituted solution. Stability depends on formulation, storage, and time after reconstitution; labeled ratio durability is source-specific, not independently established.

key facts

• molecular formula: C152H252N44O42 (CJC-1295) + C38H49N9O5 (ipamorelin)
• molecular weight: 3367.9 + 711.85 Da
• amino acids: 30 + 5
• half-life: CJC-1295: 30 min (no DAC); ipamorelin: ~2 h
• type: GHRH analog + GHRP blend
• CAS: 863288-34-0 / 170851-70-4
• 3-5x GH amplification vs. either alone
• ~10 yrs clinic practice pattern
• varies blend ratios by source
• ~70 studies combined on the individual components

frequently asked questions

What is CJC-1295 / Ipamorelin blend?

A combination of two growth hormone-stimulating peptides in a single vial: CJC-1295 (a modified GHRH analog) and Ipamorelin (a selective GHSR/ghrelin receptor agonist). Together they hit both arms of GH release, the GHRH side and the GHRP side, for synergistic pulsatile GH stimulation.

What does CJC-1295 / Ipamorelin do?

Stimulates pulsatile growth hormone release through two complementary pathways. GHRH (CJC-1295) triggers GH release from pituitary somatotrophs; GHRP (ipamorelin) amplifies the pulse via the ghrelin receptor. Sleep, recovery, skin, and body-composition claims are mostly clinic and community reports layered on component pharmacology, not direct blend RCT outcomes.

How is CJC-1295 / Ipamorelin typically administered?

Research and clinic formulations vary, and there is no FDA-approved dosing framework for either component or the blend. Community route and schedule claims should be treated as practice patterns, not label instructions.

What are the side effects of CJC-1295 / Ipamorelin?

Side effect profile is generally mild and consistent with the individual components. Common reports: transient flushing at injection, mild headache, occasional injection-site soreness, and occasional hunger from the ipamorelin half. Compared with older GHRPs, the cortisol and prolactin profile is cleaner.

Is CJC-1295 / Ipamorelin FDA approved?

No. Neither component is FDA-approved for any indication, and the blend itself has no approved use. Both are sold as research chemicals and are prohibited under WADA for competitive athletes.

How much does CJC-1295 / Ipamorelin cost?

Clinic and research-vendor pricing varies widely. Compounded access changed after the FDA's 2023 503A actions, and research-vendor products are not FDA-reviewed drugs.

related peptides

• cjc-1295 — GHRH component, the 'carry' side
• ipamorelin — GHRP component, the 'spark' side
• hgh — what this stack is designed to replace
• sermorelin — single-component GHRH alternative

reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.